# Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy

> **NCT06889402** · — · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 600 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **PROCEDURE:** Neoadjuvant therapy with PD-L1 inhibitor

## Key facts

- **NCT ID:** NCT06889402
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2025-04-15
- **Final completion:** 2025-04-30
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06889402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06889402, "Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06889402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*